Hedge Fund ADAR1 Capital Invests $37 Million in Crinetics Pharmaceuticals Following Palsonify Launch
核心洞察
ADAR1 Capital Management (搜索) disclosed a $37 million investment in Crinetics Pharmaceuticals during Q1 2026, purchasing 829,963 shares and bringing their stake to 2.44% of the fund's assets under management.
Crinetics recently launched Palsonify (搜索), its first commercial oral treatment for acromegaly (搜索), a rare hormonal disorder, with Q1 revenue significantly beating expectations despite subsequent stock price decline.
The company maintains $1.3 billion in cash reserves while burning approximately $150 million quarterly on R&D and commercialization efforts for its rare endocrine disease pipeline.
ADAR1 Capital Management (搜索) made a significant $37 million investment in Crinetics Pharmaceuticals during the first quarter of 2026, according to SEC filings disclosed on May 15, 2026. The hedge fund purchased 829,963 shares of the rare disease biotech company, bringing its total position to 2.44% of the fund's 13F reportable assets under management.
Commercial Launch Drives Investment Interest
The investment comes as Crinetics has recently launched Palsonify (搜索), its first commercial drug targeting acromegaly (搜索), a rare hormonal disorder. The oral treatment represents a significant milestone for the San Diego-based biotechnology company, which has focused on developing novel therapies for rare endocrine diseases (搜索) and related tumors.
Despite Q1 revenue significantly beating expectations for Palsonify (搜索), Crinetics stock declined following the earnings announcement. As of May 15, 2026, shares were trading at $36.77, delivering a one-year total return of 17.8%, though this performance trailed the S&P 500 by 7.4 percentage points.
Financial Position and Pipeline Development
Crinetics maintains a strong cash position of $1.3 billion, providing runway for continued operations despite quarterly cash burn of approximately $150 million on research and development and commercialization activities. The company operates under a clinical-stage biotechnology model, advancing its proprietary drug pipeline toward regulatory approval and commercial launch.
The company's strategy centers on leveraging proprietary expertise in receptor-targeted drug design to address significant unmet medical needs in rare endocrine therapeutics. Beyond Palsonify (搜索), Crinetics is developing additional pipeline candidates for other rare diseases, though none currently generate revenue.
Investment Portfolio Context
Following the Q1 transaction, Crinetics represents a notable position within ADAR1 Capital Management (搜索)'s healthcare-focused portfolio. The fund's top holdings include ABVX at $155.22 million (9.4% of AUM), PTGX at $104.78 million (6.4% of AUM), and ROIV at $91.02 million (5.5% of AUM), indicating a concentrated approach to biotech investments.
The quarter-end value of ADAR1's Crinetics position rose by $26.98 million, reflecting both the addition of shares and share price appreciation during the period. This investment represents the fund's confidence in Crinetics' commercial execution capabilities and pipeline potential in the rare disease space.